Replies to post #445649 on Amarin Corp Plc (AMRN)

[rosemountbomber]

I almost always agree with your thinking but a new indication?

Will that mean another clinical trial? 300 million wouldn't come close to covering such. Not to mention that the CVD indication gives V exclusivity and yet that means nothing as the Generics bleed into that indication and infringement would be similar with a new indication.

Now possibly this new formulation (that we mostly and not the company talk about) if there is a shortcut to approval.